@article{APS10735,
author = {Hui-fang Wang and Yi-xuan Wang and Yu-ping Zhou and Yun-peng Wei and Yi Yan and Ze-jian Zhang and Zhi-cheng Jing},
title = {Protein O -GlcNAcylation in cardiovascular diseases},
journal = {Acta Pharmacologica Sinica},
volume = {44},
number = {1},
year = {2022},
keywords = {},
abstract = {O-GlcNAcylation is a post-translational modification of protein in response to genetic variations or environmental factors, which is controlled by two highly conserved enzymes, i.e. O-GlcNAc transferase (OGT) and protein O-GlcNAcase (OGA). Protein O-GlcNAcylation mainly occurs in the cytoplasm, nucleus, and mitochondrion, and it is ubiquitously implicated in the development of cardiovascular disease (CVD). Alterations of O-GlcNAcylation could cause massive metabolic imbalance and affect cardiovascular function, but the role of O-GlcNAcylation in CVD remains controversial. That is, acutely increased O-GlcNAcylation is an adaptive heart response, which temporarily protects cardiac function. While it is harmful to cardiomyocytes if O-GlcNAcylation levels remain high in chronic conditions or in the long run. The underlying mechanisms include regulation of transcription, energy metabolism, and other signal transduction reactions induced by O-GlcNAcylation. In this review, we will focus on the interactions between protein O-GlcNAcylation and CVD, and discuss the potential molecular mechanisms that may be able to pave a new avenue for the treatment of cardiovascular events.},
issn = {1745-7254}, url = {http://www.chinaphar.com/article/view/10735}
}